EP3973586A4 - Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders - Google Patents

Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders Download PDF

Info

Publication number: EP3973586A4
Authority: EP; European Patent Office
Prior art keywords: behavioral; methods; pharmaceutical compositions; cognitive disorders; novel pharmaceutical
Prior art date: 2019-05-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP19929933.0A

Other languages

German (de)

French (fr)

Other versions

EP3973586A1 (en

Inventor

Jianmin Wang

Geping Cui

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

La Pharma Tech Inc

Original Assignee

La Pharma Tech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-05-21

Filing date

2019-05-21

Publication date

2023-01-11

2019-05-21 Application filed by La Pharma Tech Inc filed Critical La Pharma Tech Inc

2022-03-30 Publication of EP3973586A1 publication Critical patent/EP3973586A1/en

2023-01-11 Publication of EP3973586A4 publication Critical patent/EP3973586A4/en

Status Pending legal-status Critical Current

Links

230000003542 behavioural effect Effects 0.000 title 1
208000010877 cognitive disease Diseases 0.000 title 1
230000003340 mental effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P70/00—Climate change mitigation technologies in the production process for final industrial or consumer products
- Y02P70/50—Manufacturing or production processes characterised by the final manufactured product

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP19929933.0A 2019-05-21 2019-05-21 Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders Pending EP3973586A4 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2019/033359 WO2020236159A1 (en)	2019-05-21	2019-05-21	Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Publications (2)

Publication Number	Publication Date
EP3973586A1 EP3973586A1 (en)	2022-03-30
EP3973586A4 true EP3973586A4 (en)	2023-01-11

Family

ID=73459142

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19929933.0A Pending EP3973586A4 (en)	2019-05-21	2019-05-21	Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Country Status (6)

Country	Link
EP (1)	EP3973586A4 (en)
JP (1)	JP2022539944A (en)
CN (1)	CN114072945A (en)
AU (1)	AU2019446955A1 (en)
CA (1)	CA3139082A1 (en)
WO (1)	WO2020236159A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11938139B2 (en)	2019-04-12	2024-03-26	LA PharmaTech Inc.	Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11389458B2 (en)	2019-04-12	2022-07-19	LA PharmaTech Inc.	Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11318144B2 (en)	2019-04-12	2022-05-03	LA PharmaTech Inc.	Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10639314B1 (en)	2019-04-30	2020-05-05	LA PharmaTech Inc.	Method of treating Alzheimer's disease
US10966989B2 (en)	2019-04-12	2021-04-06	LA PharmaTech Inc.	Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11744833B2 (en)	2019-04-12	2023-09-05	LA PharmaTech Inc.	Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en)	2019-04-12	2023-07-04	LA PharmaTech Inc.	Method of treating dementia
US11351179B1 (en)	2021-08-05	2022-06-07	LA PharmaTech Inc.	Pharmaceutical compositions and methods for treatment of psychiatric disorders
WO2024072049A1 (en) *	2022-09-26	2024-04-04	주식회사 지투지바이오	Pharmaceutical combination containing donepezil and rivastigmine for preventing, alleviating or treating dementia or cognitive impairment, and preparation method therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100152108A1 (en) *	2006-10-27	2010-06-17	Medivation Neurology, Inc.	Methods and combination therapies for treating alzheimer's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1298715C (en) *	2001-03-13	2007-02-07	先灵公司	Non-imidazole compounds as histamine H3 antagonists
US7491748B2 (en) *	2001-08-09	2009-02-17	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
US7355042B2 (en) *	2001-10-16	2008-04-08	Hypnion, Inc.	Treatment of CNS disorders using CNS target modulators
FR2974729B1 (en) *	2011-05-02	2013-04-19	Servier Lab	NOVEL ASSOCIATION BETWEEN 4- {3- [CIS-HEXAHYDROCYCLOPENTA [C] PYRROL-2 (1H) -YL] PROPOXY} BENZAMIDE AND AN ACETYLCHOLINESTERASE INHIBITOR AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
SG11201601306QA (en) *	2013-09-09	2016-03-30	Sanofi Sa	An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

2019
- 2019-05-21 AU AU2019446955A patent/AU2019446955A1/en not_active Abandoned
- 2019-05-21 WO PCT/US2019/033359 patent/WO2020236159A1/en unknown
- 2019-05-21 JP JP2021566489A patent/JP2022539944A/en active Pending
- 2019-05-21 CN CN201980096574.4A patent/CN114072945A/en active Pending
- 2019-05-21 CA CA3139082A patent/CA3139082A1/en active Pending
- 2019-05-21 EP EP19929933.0A patent/EP3973586A4/en active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100152108A1 (en) *	2006-10-27	2010-06-17	Medivation Neurology, Inc.	Methods and combination therapies for treating alzheimer's disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AIKO HATAKEYAMA ET AL: "AZELASTINE HYDROCHLORIDE ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND ACTIVITIES OF DAILY LIVING IN DEMENTIA PATIENTS", GERIATR. GERONTOL. INT,, vol. 8, 1 January 2008 (2008-01-01), pages 59 - 61, XP002798078 *
ANONYMOUS: "Donepezil -Medline Plus", MEDLINE PLUS, 15 December 2017 (2017-12-15), pages 1 - 7, XP093003741, Retrieved from the Internet <URL:https://medlineplus.gov/druginfo/meds/a697032.html> [retrieved on 20221130] *
ANONYMOUS: "EPAR summary for the public", EUROPEAN MEDICINES AGENCY, 1 December 2012 (2012-12-01), pages 1 - 3, XP093003735, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/overview/prometax-epar-summary-public_en.pdf> [retrieved on 20221130] *
ANONYMOUS: "RAZADYNE-galantamine hydrobromide tablet, film coated Rebel Dis tributors Corp", DAILYMED, 11 November 2010 (2010-11-11), pages 1 - 29, XP093003743, Retrieved from the Internet <URL:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e62efb5a-d2cc-4e11-9e61-10e65ef3d897> [retrieved on 20221130] *
See also references of WO2020236159A1 *

Also Published As

Publication number	Publication date
EP3973586A1 (en)	2022-03-30
CA3139082A1 (en)	2020-11-26
CN114072945A (en)	2022-02-18
AU2019446955A1 (en)	2021-12-23
WO2020236159A1 (en)	2020-11-26
JP2022539944A (en)	2022-09-14

Legal Events

Date	Code	Title	Description
2020-11-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2022-02-25	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-02-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2022-03-30	17P	Request for examination filed	Effective date: 20211221
2022-03-30	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-08-24	DAV	Request for validation of the european patent (deleted)
2022-08-24	DAX	Request for extension of the european patent (deleted)
2022-12-08	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: H01M0010040000 Ipc: A61K0031270000
2023-01-11	A4	Supplementary search report drawn up and despatched	Effective date: 20221214
2023-01-11	RIC1	Information provided on ipc code assigned before grant	Ipc: H01M 4/00 20060101ALI20221208BHEP Ipc: H01M 10/26 20060101ALI20221208BHEP Ipc: H01M 10/04 20060101ALI20221208BHEP Ipc: A61P 25/28 20060101ALI20221208BHEP Ipc: A61K 31/55 20060101ALI20221208BHEP Ipc: A61K 31/445 20060101ALI20221208BHEP Ipc: A61K 31/27 20060101AFI20221208BHEP
2024-02-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2024-03-13	17Q	First examination report despatched	Effective date: 20240206

Publication	Publication Date	Title
EP3952840A4 (en)	2022-11-23	Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
EP3973586A4 (en)	2023-01-11	Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
EP3351616A4 (en)	2019-05-01	Novel lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders
EP3675859A4 (en)	2021-06-30	Compounds, compositions, and methods for the treatment of disease
EP3931189A4 (en)	2022-11-30	Azepino-indoles and other heterocycles for treating brain disorders
EP3934652A4 (en)	2022-12-07	Compounds, compositions, and methods for the treatment of disease
EP3962488A4 (en)	2022-12-14	A method of treating mental, behavioral, cognitive disorders
EP3906043A4 (en)	2022-10-26	Methods and compositions for the treatment of fabry disease
EP3681477A4 (en)	2021-06-09	Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
EP3999084A4 (en)	2023-07-12	Methods and products for treatment of gastrointestinal disorders
EP3507371A4 (en)	2020-08-05	Methods and compositions for treating diseases and disorders of the nervous system
EP3858353A4 (en)	2022-07-06	Pharmaceutical composition for preventing and treating nitm and pharmaceutical use thereof
EP3492096A4 (en)	2020-04-15	Pharmaceutical composition for treating ocular diseases, containing cas9 protein and guide rna
EP3818085A4 (en)	2022-03-09	Compositions and uses thereof for treating disease or condition
EP3934646A4 (en)	2022-12-14	Pharmaceutical compositions for treating ocular diseases or disorders
EP3755319A4 (en)	2021-12-01	Compounds and compositions for the treatment of muscular disorders
EP4034109A4 (en)	2023-10-18	Method and composition for the treatment of disease
EP3570670A4 (en)	2020-07-22	Compositions and methods for treating lysosomal storage diseases and disorders
EP3943107A4 (en)	2022-12-07	Composition for preventing or treating brain and nervous system disease
EP3600324A4 (en)	2020-12-09	Drugs and compositions for the treatment of ocular disorders
EP3558281A4 (en)	2020-07-08	Treatment of mental, movement and behavioral disorders
EP4043012A4 (en)	2024-01-24	Drug for treating artery-related diseases, and use thereof
EP3979985A4 (en)	2023-05-03	Compositions and methods for treating central nervous system disorders
EP3946433A4 (en)	2023-01-18	Compositions, devices and methods for treating fabry disease
EP4010075A4 (en)	2023-11-15	Methods for the treatment of apoc3-related diseases and disorders